Clinical Trials · NCT00842348
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 89
- Start date
- Feb 2009
- Locations
- 25 sites, 9 countries
- Primary endpoint
- Adverse Events